Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.40
CBST's Cash to Debt is ranked higher than
50% of the 1233 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. CBST: 0.40 )
CBST' s 10-Year Cash to Debt Range
Min: 0.19   Max: 35.27
Current: 0.4

0.19
35.27
Equity to Asset 0.48
CBST's Equity to Asset is ranked higher than
61% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CBST: 0.48 )
CBST' s 10-Year Equity to Asset Range
Min: -0.48   Max: 0.95
Current: 0.48

-0.48
0.95
Interest Coverage 0.70
CBST's Interest Coverage is ranked lower than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBST: 0.70 )
CBST' s 10-Year Interest Coverage Range
Min: 0.31   Max: 9.73
Current: 0.7

0.31
9.73
F-Score: 5
Z-Score: 2.85
M-Score: -2.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 10.54
CBST's Operating margin (%) is ranked higher than
88% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -80.68 vs. CBST: 10.54 )
CBST' s 10-Year Operating margin (%) Range
Min: -2763   Max: 29.79
Current: 10.54

-2763
29.79
Net-margin (%) 5.59
CBST's Net-margin (%) is ranked higher than
86% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. CBST: 5.59 )
CBST' s 10-Year Net-margin (%) Range
Min: -3094.81   Max: 39.16
Current: 5.59

-3094.81
39.16
ROE (%) 4.49
CBST's ROE (%) is ranked higher than
88% of the 1124 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. CBST: 4.49 )
CBST' s 10-Year ROE (%) Range
Min: -5818.4   Max: 82.7
Current: 4.49

-5818.4
82.7
ROA (%) 2.10
CBST's ROA (%) is ranked higher than
88% of the 1231 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. CBST: 2.10 )
CBST' s 10-Year ROA (%) Range
Min: -66.79   Max: 27.15
Current: 2.1

-66.79
27.15
ROC (Joel Greenblatt) (%) 13.93
CBST's ROC (Joel Greenblatt) (%) is ranked higher than
90% of the 1204 Companies
in the Global Biotechnology industry.

( Industry Median: -480.34 vs. CBST: 13.93 )
CBST' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -242.38   Max: 141.6
Current: 13.93

-242.38
141.6
Revenue Growth (%) 15.00
CBST's Revenue Growth (%) is ranked higher than
88% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. CBST: 15.00 )
CBST' s 10-Year Revenue Growth (%) Range
Min: -45.9   Max: 209.9
Current: 15

-45.9
209.9
EBITDA Growth (%) -43.60
CBST's EBITDA Growth (%) is ranked higher than
55% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. CBST: -43.60 )
CBST' s 10-Year EBITDA Growth (%) Range
Min: -46.9   Max: 93.6
Current: -43.6

-46.9
93.6
» CBST's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

CBST Guru Trades in Q4 2013

Paul Tudor Jones 3,348 sh (New)
Andreas Halvorsen 741,700 sh (+24.72%)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Stanley Druckenmiller 413,000 sh (unchged)
Murray Stahl 24,000 sh (unchged)
John Burbank Sold Out
Joel Greenblatt Sold Out
George Soros 144,500 sh (-3.67%)
RS Investment Management 536,011 sh (-13.83%)
Pioneer Investments 515,939 sh (-24.84%)
Chuck Royce 307,800 sh (-27.71%)
Steven Cohen 30,257 sh (-49.99%)
Jim Simons 125,920 sh (-61.21%)
» More
Q1 2014

CBST Guru Trades in Q1 2014

Lee Ainslie 1,739,818 sh (New)
Jim Simons 189,091 sh (+50.17%)
Murray Stahl 24,000 sh (unchged)
Vanguard Health Care Fund 1,323,142 sh (unchged)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Stanley Druckenmiller Sold Out
RS Investment Management 504,845 sh (-5.81%)
Chuck Royce 219,900 sh (-28.56%)
Pioneer Investments 368,542 sh (-28.57%)
George Soros 50,000 sh (-65.4%)
Steven Cohen 3,082 sh (-89.81%)
» More
Q2 2014

CBST Guru Trades in Q2 2014

Ken Fisher 36,450 sh (New)
Vanguard Health Care Fund 1,467,542 sh (+10.91%)
Steven Cohen 394,200 sh (unchged)
Murray Stahl 24,000 sh (unchged)
George Soros Sold Out
Lee Ainslie Sold Out
Pioneer Investments 358,881 sh (-2.62%)
Chuck Royce 211,600 sh (-3.77%)
RS Investment Management 390,565 sh (-22.64%)
Jim Simons 47,420 sh (-74.92%)
» More
Q3 2014

CBST Guru Trades in Q3 2014

Vanguard Health Care Fund 1,977,342 sh (+34.74%)
Murray Stahl 24,000 sh (unchged)
Jim Simons Sold Out
RS Investment Management Sold Out
Ken Fisher 34,775 sh (-4.6%)
Pioneer Investments 338,388 sh (-5.71%)
Chuck Royce 197,980 sh (-6.44%)
Steven Cohen 340,200 sh (-13.7%)
» More
» Details

Insider Trades

Latest Guru Trades with CBST

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2014-09-30 Add 34.74%0.09%$60.5 - $70.58 $ 73.3712%1977342
Lee Ainslie 2014-06-30 Sold Out 1.8%$61.66 - $74.27 $ 73.378%0
George Soros 2014-06-30 Sold Out 0.04%$61.66 - $74.27 $ 73.378%0
Ken Fisher 2014-06-30 New Buy0.01%$61.66 - $74.27 $ 73.378%36450
Lee Ainslie 2014-03-31 New Buy1.8%$67.2 - $81.23 $ 73.37-1%1739818
Andreas Halvorsen 2014-03-31 Sold Out 0.24%$67.2 - $81.23 $ 73.37-1%0
George Soros 2014-03-31 Reduce -65.4%0.06%$67.2 - $81.23 $ 73.37-1%50000
John Burbank 2013-12-31 Sold Out 0.42%$61.59 - $70.76 $ 73.3714%0
Joel Greenblatt 2013-12-31 Sold Out 0.05%$61.59 - $70.76 $ 73.3714%0
Andreas Halvorsen 2013-12-31 Add 24.72%0.05%$61.59 - $70.76 $ 73.3714%741700
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 90.70
CBST's P/E(ttm) is ranked higher than
89% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 90.70 )
CBST' s 10-Year P/E(ttm) Range
Min: 7.41   Max: 3802.11
Current: 90.7

7.41
3802.11
P/B 3.61
CBST's P/B is ranked higher than
81% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 5.68 vs. CBST: 3.61 )
CBST' s 10-Year P/B Range
Min: 1.85   Max: 81.28
Current: 3.61

1.85
81.28
P/S 5.23
CBST's P/S is ranked higher than
89% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 32.77 vs. CBST: 5.23 )
CBST' s 10-Year P/S Range
Min: 1.98   Max: 150
Current: 5.23

1.98
150
PFCF 49.24
CBST's PFCF is ranked higher than
95% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 49.24 )
CBST' s 10-Year PFCF Range
Min: 8.06   Max: 277.85
Current: 49.24

8.06
277.85
EV-to-EBIT 54.03
CBST's EV-to-EBIT is ranked higher than
89% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 54.03 )
CBST' s 10-Year EV-to-EBIT Range
Min: -341   Max: 265.1
Current: 54.03

-341
265.1
Shiller P/E 57.59
CBST's Shiller P/E is ranked higher than
95% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 57.59 )
CBST' s 10-Year Shiller P/E Range
Min: 23.16   Max: 105.2
Current: 57.59

23.16
105.2
Current Ratio 3.54
CBST's Current Ratio is ranked higher than
68% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. CBST: 3.54 )
CBST' s 10-Year Current Ratio Range
Min: 0.9   Max: 14.48
Current: 3.54

0.9
14.48
Quick Ratio 3.29
CBST's Quick Ratio is ranked higher than
67% of the 1225 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CBST: 3.29 )
CBST' s 10-Year Quick Ratio Range
Min: 0.81   Max: 14.48
Current: 3.29

0.81
14.48

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 2.27
CBST's Price/DCF (Projected) is ranked higher than
96% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CBST: 2.27 )
CBST' s 10-Year Price/DCF (Projected) Range
Min: 0.72   Max: 6.9
Current: 2.27

0.72
6.9
Price/Median PS Value 1.21
CBST's Price/Median PS Value is ranked higher than
83% of the 1314 Companies
in the Global Biotechnology industry.

( Industry Median: 2.89 vs. CBST: 1.21 )
CBST' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 86.77
Current: 1.21

0.52
86.77
Earnings Yield (Greenblatt) 1.90
CBST's Earnings Yield (Greenblatt) is ranked higher than
89% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. CBST: 1.90 )
CBST' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 23.3
Current: 1.9

0.4
23.3
Forward Rate of Return (Yacktman) -14.46
CBST's Forward Rate of Return (Yacktman) is ranked higher than
69% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -6.43 vs. CBST: -14.46 )
CBST' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -38.4   Max: 66.3
Current: -14.46

-38.4
66.3

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CU6.Germany
Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.
» More Articles for CBST

Headlines

Articles On GuruFocus.com
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Weekly CEO Sells Highlight: Saba Software Inc, Cubist Pharmaceuticals Inc, Polo Ralph Lauren Corp, P Apr 25 2010 
Cubist Pharmaceuticals Inc. (CBST) President and CEO Michael W Bonney sells 184,548 Shares Apr 23 2010 
Cubist Pharmaceuticals: A Drug Stock With Potential For Solid Gain Feb 15 2010 

More From Our Partners
Is This Superbug Drug Company Right for Your Portfolio? Nov 19 2014 - FOXBUSINESS

More From Other Websites
Is This Superbug Drug Company Right for Your Portfolio? Nov 19 2014
European Antibiotic Awareness Day Highlights Need for Urgent Action Nov 17 2014
European Antibiotic Awareness Day Highlights Need for Urgent Action Nov 17 2014
European Antibiotic Awareness Day Highlights Need for Urgent Action Nov 17 2014
CUBIST PHARMACEUTICALS INC Financials Nov 14 2014
10-Q for Cubist Pharmaceuticals, Inc. Nov 10 2014
CUBIST PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits Nov 06 2014
Cubist Pharmaceuticals (CBST) Upgraded From Hold to Buy Nov 05 2014
Cubist Names Dr. Patrick Vink Chief Operating Officer Nov 05 2014
Cubist Names Dr. Patrick Vink Chief Operating Officer Nov 05 2014
Wedbush Initiates Coverage On Cubist Pharmaceuticals Nov 04 2014
Cubist to Present at Jefferies 2014 Healthcare Conference Nov 03 2014
Cubist to Present at Jefferies 2014 Healthcare Conference Nov 03 2014
Cubist to Present at Jefferies 2014 Healthcare Conference Nov 03 2014
Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Oct 29 2014
Cubist Pharmaceuticals' Q3 Earnings Beat Expectations Oct 23 2014
Today's Market Thorns, Roses, and All Time Highs... Oct 22 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Financial Statements and Exhibits Oct 22 2014
Trade-Ideas: Cubist Pharmaceuticals (CBST) Is Today's "Storm The Castle" Stock Oct 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK